IRVINE, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (Nasdaq:CBMX) announced today that it will release its second quarter 2014 financial results on Wednesday, August 6, 2014. Results will be released after the close of trading on that day.
A conference call has also been scheduled regarding CombiMatrix Corporation's second quarter 2014 financial results. The presentation and Q&A session will start at 1:30 p.m. PDT (4:30 p.m. EDT) on August 6, 2014.
To attend the presentation by phone, dial 1-877-407-0784 for domestic callers and 1-201-689-8560 for direct-dial or international callers. The call will be webcast live under the investor relations section of the CombiMatrix's website, at www.combimatrix.com.
Date: August 6, 2014
Time: 4:30 PM ET
Listen via Internet: http://investor.combimatrix.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted): http://apps.shareholder.com/PNWOutlook/t.aspx?m=65687&k=FA64718F
A replay of the presentation will be available following the presentation, either via the CombiMatrix website Investor/Events section (http://investor.combimatrix.com/events.cfm) or by dialing 1-877-870-5176 for domestic callers or 1-858-384-5517 for direct-dial international callers. When prompted, enter playback pin number 13587798.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic solutions and comprehensive clinical support to foster the highest quality in patient care. CombiMatrix specializes in miscarriage analysis, prenatal testing and pediatric genetics, offering DNA based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray, standardized and customized fluorescence in situ hybridization ("FISH") and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making. Additional information about CombiMatrix is available at www.combimatrix.com or by calling 1-800-710-0624.
CONTACT: Company Contact: Mark McDonough President & CEO, CombiMatrix Corporation Tel (949) 753-0624 Media Contact: David Schull or Lena Evans Russo Partners LLC (212) 845-4271 or (212) 845-4262 email@example.com firstname.lastname@example.org Investor Contact: Robert Flamm, Ph.D. Russo Partners, LLC (212) 845-4226 email@example.com